A team reported cryopreservable dopaminergic progenitors derived from human iPSCs that can be stored and later transplanted, demonstrating early functional restoration in Parkinsonian rat models. The work highlights a technical hurdle for stem-cell therapy—loss of pluripotency during processing—and presents an approach intended to improve feasibility. In preclinical testing, the transplanted progenitors contributed to recovery of function, supporting the possibility of more practical cell therapy logistics through cryopreservation. Progression to clinical evaluation will require careful assessment of safety, tumorigenicity risk controls, and long-term functional outcomes.